Evaluation of the efficacy and safety of QMF149 vs Mometasone in patients with asthma

Mise à jour : Il y a 4 ans
Référence : EUCTR2015-002529-21

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To demonstrate the superiority of either QMF149 150/160 μg delivered via Concept1 o.d. (in the evening) to MF 400 μg o.d (in the evening) delivered via Twisthaler® or QMF149 150/320 μg delivered via Concept1 o.d. (in the evening) to MF 800 μg delivered via Twisthaler® (delivered as 400 μg b.i.d.) in terms of FEV1 at 26 weeks.


Critère d'inclusion

  • Asthma